MS patients may benefit from switching Immune-Suppressing drugs

NCT ID NCT06854094

Ongoing Disease control Sponsor: Ente Ospedaliero Cantonale, Bellinzona Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether switching from anti-CD20 drugs (like ocrelizumab) to cladribine can help restore immune function and reduce infections in people with relapsing multiple sclerosis. About 70 participants will be followed for 2 years. The goal is to see if the switch improves antibody levels and lowers infection risk compared to staying on anti-CD20 therapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cladribine
What this could lead to: If successful, this could show that switching to cladribine helps restore immune function and lowers infection risk for MS patients on long-term anti-CD20 therapy.
What could go wrong: This is a relatively small study (70 people) and results may not apply to all MS patients. The switch might not improve immunity or could cause other side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis relapsing-remitting multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS

Contacts and locations

Locations

Ospedale Regionale di Lugano, Istituto di Neuroscienze Cliniche della Svizzera Italiana, Via Tesserete 46,

Lugano, Canton Ticino, 6903, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.